These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 32891803)

  • 21. PCSK9 Inhibitor Use in the Real World: Data From the National Patient-Centered Research Network.
    Chamberlain AM; Gong Y; Shaw KM; Bian J; Song WL; Linton MF; Fonseca V; Price-Haywood E; Guhl E; King JB; Shah RU; Puro J; Shenkman E; Pawloski PA; Margolis KL; Hernandez AF; Cooper-DeHoff RM
    J Am Heart Assoc; 2019 May; 8(9):e011246. PubMed ID: 31020929
    [TBL] [Abstract][Full Text] [Related]  

  • 22. How much should LDL cholesterol be lowered in secondary prevention? Clinical efficacy and safety in the era of PCSK9 inhibitors.
    Cybulska B; Kłosiewicz-Latoszek L; Penson PE; Nabavi SM; Lavie CJ; Banach M;
    Prog Cardiovasc Dis; 2021; 67():65-74. PubMed ID: 33383060
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Updated Cost-effectiveness Assessments of PCSK9 Inhibitors From the Perspectives of the Health System and Private Payers: Insights Derived From the FOURIER Trial.
    Arrieta A; Hong JC; Khera R; Virani SS; Krumholz HM; Nasir K
    JAMA Cardiol; 2017 Dec; 2(12):1369-1374. PubMed ID: 29049467
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment with PCSK9 inhibitors reduces atherogenic VLDL remnants in a real-world study.
    Hollstein T; Vogt A; Grenkowitz T; Stojakovic T; März W; Laufs U; Bölükbasi B; Steinhagen-Thiessen E; Scharnagl H; Kassner U
    Vascul Pharmacol; 2019 May; 116():8-15. PubMed ID: 30910670
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lipid management in ACS: Should we go lower faster?
    Gencer B; Mach F
    Atherosclerosis; 2018 Aug; 275():368-375. PubMed ID: 30015301
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes.
    Roe MT; Li QH; Bhatt DL; Bittner VA; Diaz R; Goodman SG; Harrington RA; Jukema JW; Lopez-Jaramillo P; Lopes RD; Louie MJ; Moriarty PM; Szarek M; Vogel R; White HD; Zeiher AM; Baccara-Dinet MT; Steg PG; Schwartz GG
    Circulation; 2019 Nov; 140(19):1578-1589. PubMed ID: 31475572
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Eligibility for alirocumab or evolocumab treatment in 1090 hypercholesterolemic patients referred to a regional cholesterol treatment center with LDL cholesterol ≥70 mg/dL despite maximal-tolerated LDL-cholesterol-lowering therapy.
    Jetty V; Glueck CJ; Lee K; Goldenberg N; Prince M; Kumar A; Goldenberg M; Anand I; Wang P
    Vasc Health Risk Manag; 2017; 13():247-253. PubMed ID: 28740397
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cohort Study Examining the Association of Immunosuppressant Drug Prescription With Major Adverse Cardiovascular and Limb Events in Patients With Peripheral Artery Disease.
    Golledge J; Velu R; Quigley F; Jenkins J; Singh TP
    Ann Vasc Surg; 2022 Jan; 78():310-320. PubMed ID: 34537348
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Proprotein Convertase Subtilisin-Kexin Type 9 (PCSK9) Inhibitors and Cardiovascular Risk: Does a Further Analysis of the Fourier Trial Suggest Changes in the Target of Lipid Lowering Therapy?
    Cervelli N; Tocci G; Ferri C
    High Blood Press Cardiovasc Prev; 2018 Mar; 25(1):5-7. PubMed ID: 29305812
    [No Abstract]   [Full Text] [Related]  

  • 30. Clinical Benefit of Evolocumab by Severity and Extent of Coronary Artery Disease: Analysis From FOURIER.
    Sabatine MS; De Ferrari GM; Giugliano RP; Huber K; Lewis BS; Ferreira J; Kuder JF; Murphy SA; Wiviott SD; Kurtz CE; Honarpour N; Keech AC; Sever PS; Pedersen TR
    Circulation; 2018 Aug; 138(8):756-766. PubMed ID: 29626068
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cardiovascular Outcomes and Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: Current Data and Future Prospects.
    Duprez DA; Handelsman Y; Koren M
    Vasc Health Risk Manag; 2020; 16():403-418. PubMed ID: 33116551
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical efficacy and safety of evolocumab for low-density lipoprotein cholesterol reduction.
    Henry CA; Lyon RA; Ling H
    Vasc Health Risk Manag; 2016; 12():163-9. PubMed ID: 27143910
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PCSK9 Inhibitors in Secondary Prevention-An Opportunity for Personalized Therapy.
    Board C; Kelly MS; Shapiro MD; Dixon DL
    J Cardiovasc Pharmacol; 2020 May; 75(5):410-420. PubMed ID: 32379108
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Retrospective Chart Review Evaluating Efficacy, Tolerability, and Cost of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors (PCSK9i) in Older Adults.
    Davis LE; Pogge EK
    High Blood Press Cardiovasc Prev; 2020 Aug; 27(4):331-338. PubMed ID: 32651891
    [TBL] [Abstract][Full Text] [Related]  

  • 35. From lipoprotein apheresis to proprotein convertase subtilisin/kexin type 9 inhibitors: Impact on low-density lipoprotein cholesterol and C-reactive protein levels in cardiovascular disease patients.
    Zenti MG; Altomari A; Lupo MG; Botta M; Bonora E; Corsini A; Ruscica M; Ferri N
    Eur J Prev Cardiol; 2018 Nov; 25(17):1843-1851. PubMed ID: 30058841
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Alirocumab therapy in individuals with type 2 diabetes mellitus and atherosclerotic cardiovascular disease: analysis of the ODYSSEY DM-DYSLIPIDEMIA and DM-INSULIN studies.
    Ray KK; Del Prato S; Müller-Wieland D; Cariou B; Colhoun HM; Tinahones FJ; Domenger C; Letierce A; Mandel J; Samuel R; Bujas-Bobanovic M; Leiter LA
    Cardiovasc Diabetol; 2019 Nov; 18(1):149. PubMed ID: 31706300
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PCSK9 inhibition 2018: riding a new wave of coronary prevention.
    Ward NC; Page MM; Watts GF
    Clin Sci (Lond); 2019 Jan; 133(2):205-224. PubMed ID: 30670671
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pleiotropic Effects of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibitors?
    Bittner V
    Circulation; 2016 Nov; 134(22):1695-1696. PubMed ID: 27895023
    [No Abstract]   [Full Text] [Related]  

  • 39. Efficacy and safety of proprotein convertase subtilisin/kexin 9 inhibitors in people with diabetes and dyslipidaemia.
    Dijk W; Cariou B
    Diabetes Obes Metab; 2019 Apr; 21 Suppl 1():39-51. PubMed ID: 31002456
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phenome-wide association analysis of LDL-cholesterol lowering genetic variants in PCSK9.
    Schmidt AF; Holmes MV; Preiss D; Swerdlow DI; Denaxas S; Fatemifar G; Faraway R; Finan C; Valentine D; Fairhurst-Hunter Z; Hartwig FP; Horta BL; Hypponen E; Power C; Moldovan M; van Iperen E; Hovingh K; Demuth I; Norman K; Steinhagen-Thiessen E; Demuth J; Bertram L; Lill CM; Coassin S; Willeit J; Kiechl S; Willeit K; Mason D; Wright J; Morris R; Wanamethee G; Whincup P; Ben-Shlomo Y; McLachlan S; Price JF; Kivimaki M; Welch C; Sanchez-Galvez A; Marques-Vidal P; Nicolaides A; Panayiotou AG; Onland-Moret NC; van der Schouw YT; Matullo G; Fiorito G; Guarrera S; Sacerdote C; Wareham NJ; Langenberg C; Scott RA; Luan J; Bobak M; Malyutina S; Pająk A; Kubinova R; Tamosiunas A; Pikhart H; Grarup N; Pedersen O; Hansen T; Linneberg A; Jess T; Cooper J; Humphries SE; Brilliant M; Kitchner T; Hakonarson H; Carrell DS; McCarty CA; Lester KH; Larson EB; Crosslin DR; de Andrade M; Roden DM; Denny JC; Carty C; Hancock S; Attia J; Holliday E; Scott R; Schofield P; O'Donnell M; Yusuf S; Chong M; Pare G; van der Harst P; Said MA; Eppinga RN; Verweij N; Snieder H; ; Christen T; Mook-Kanamori DO; ; Gustafsson S; Lind L; Ingelsson E; Pazoki R; Franco O; Hofman A; Uitterlinden A; Dehghan A; Teumer A; Baumeister S; Dörr M; Lerch MM; Völker U; Völzke H; Ward J; Pell JP; Meade T; Christophersen IE; Maitland-van der Zee AH; Baranova EV; Young R; Ford I; Campbell A; Padmanabhan S; Bots ML; Grobbee DE; Froguel P; Thuillier D; Roussel R; Bonnefond A; Cariou B; Smart M; Bao Y; Kumari M; Mahajan A; Hopewell JC; Seshadri S; ; Dale C; Costa RPE; Ridker PM; Chasman DI; Reiner AP; Ritchie MD; Lange LA; Cornish AJ; Dobbins SE; Hemminki K; Kinnersley B; Sanson M; Labreche K; Simon M; Bondy M; Law P; Speedy H; Allan J; Li N; Went M; Weinhold N; Morgan G; Sonneveld P; Nilsson B; Goldschmidt H; Sud A; Engert A; Hansson M; Hemingway H; Asselbergs FW; Patel RS; Keating BJ; Sattar N; Houlston R; Casas JP; Hingorani AD
    BMC Cardiovasc Disord; 2019 Oct; 19(1):240. PubMed ID: 31664920
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.